BEGIN:VCALENDAR VERSION:2.0 PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4// BEGIN:VEVENT UID:20260120T234010EST-88417idGcI@132.216.98.100 DTSTAMP:20260121T044010Z DESCRIPTION:\nSupported by the generosity of the Killam Trusts\, The Neuro' s Killam Seminar Series invites outstanding guest speakers whose research is of interest to the scientific community at The Neuro and ɫֱ Univers ity.\n\n\nRegister Now\n\nTo watch online\, click here\n\nHost: Gassan Mas sarweh\n\n\n \n\nPET Neuroimaging in Drug Discovery\n\nNeil Vasdev\n Brain H ealth Imaging Centre\, Centre for Addiction and Mental Health (CAMH) & Dep artment of Psychiatry\, University of Toronto\n\nAbstract: This presentati on will focus on some non-traditional approaches to prepare radiopharmaceu ticals for new targets to image the human brain and aims to show the intri cacies of developing radiopharmaceuticals from 'bench to bedside'. Specifi cally\, cutting-edge approaches and technologies for imaging receptors and signal transduction pathways with PET\, as well as our recent work to exp and beyond the “amyloid cascade hypothesis” of Alzheimer’s disease\, inclu ding tauopathies\, will be presented. Several of the neuroimaging agents h ave also been applied as oncology probes\, and examples where we have been “learning from cancer” imaging research will be discussed. An outlook wit h examples of how academic-pharma partnerships have shaped our imaging pro gram and the vision for a Canada-wide training program for radiopharmaceut ical and medical imaging sciences will also be highlighted. The intricacie s of transitioning labeled compounds to PET radiopharmaceuticals and our a spiration to work towards the ultimate\, albeit impossible\, goal in the f ield: to radiolabel virtually any compound for PET will be raised as point s for discussion.\n\nProf. Neil Vasdev is the Director and Chief Radiochem ist of the Centre for Addiction and Mental Health (CAMH) Brain Health Imag ing Centre\, and the Director of the Azrieli Centre for Neuro-Radiochemist ry. He is a Tier 1 Canada Research Chair in Radiochemistry and Medical Ima ging\, the endowed Azrieli Chair in Brain and Behaviour and Professor of P sychiatry at the University of Toronto. Neil trained in chemistry and neur oscience for his undergraduate training and continued to complete a PhD su pported by NSERC at McMaster University\, and subsequently completed an NS ERC postdoctoral fellowship at Berkeley National Laboratories. He began hi s faculty career at CAMH/University of Toronto in 2004. In 2011\, he was r ecruited as faculty to the Massachusetts General Hospital and Harvard Medi cal School and was recruited back to Toronto in 2018. His research focuses on the development of new PET radiopharmaceuticals for imaging the living human brain\, with a particular interest in neurodegenerative diseases in cluding tauopathies. He has published over 200 peer-reviewed articles and delivered over 200 invited lectures and holds over 10 families of patents. He is a Fellow of the American Chemical Society\, Royal Society of Chemis try\, and the Society of Nuclear Medicine and Molecular Imaging.\n DTSTART:20260113T210000Z DTEND:20260113T220000Z LOCATION:de Grandpre Communications Centre\, The Neuro SUMMARY:Killam Seminar Series: PET Neuroimaging in Drug Discovery URL:/neuro/channels/event/killam-seminar-series-pet-ne uroimaging-drug-discovery-370153 END:VEVENT END:VCALENDAR